What is Survodutide?

An investigational long-acting GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

Survodutide in the library · Metabolic & Weight Peptides · Human Trials · What are peptides?

35 registered trials · 15 indexed papers · 32 human / 7 animal studies

From the PeptideWhiz library entry. "As described" sections summarize claims made in the sources; they are not PeptideWhiz endorsements.

What it is

Survodutide, also called BI 456906, is described as an investigational peptide that activates GLP-1 and glucagon receptors. Researchers are studying it for obesity and metabolic liver disease.

Phase 3 weight-loss results are described as available, but positive trials are described as not the same as regulatory approval.

Overview (as described)

  • A long-acting glucagon/GLP-1 receptor dual agonist developed through a partnership between Zealand Pharma and Boehringer Ingelheim; Boehringer Ingelheim is responsible for clinical development and commercialization.
  • It is being investigated as a once-weekly subcutaneous treatment. Its research programs include obesity, type 2 diabetes-associated obesity, and metabolic dysfunction-associated steatohepatitis (MASH), a liver condition involving inflammation and injury.

Mechanism (as described)

  • The design combines GLP-1 receptor activity with glucagon receptor activity. The program sought to keep glucose-lowering effects while adding glucagon-related effects on energy metabolism and the liver.
  • Laboratory receptor tests and mouse experiments helped select it for clinical development. The mechanism is described as a reason to study the drug, not proof of superiority over every GLP-1 medicine.

Registered human trials (35)

TrialPhaseStatusYearEnrolled
ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver DiseasePhase 3not yet recruiting2026600
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarPhase 3recruiting2026600
SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose WeightPhase 3not yet recruiting2026600
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPhase 3not yet recruiting2026350
A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityPhase 1recruiting202644
A Study in Healthy People or Otherwise Healthy With Overweight or Obesity to Compare 2 Formulations of Survodutide Given in Different Ways, Either as a Pre-filled Syringe or a Pen-like InjectorPhase 1completed202656
Albuminuria Reduction Study With Survodutide Treatment in Kidney DiseasePhase 2not yet recruiting2026120
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyPhase 1completed2025100
A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With ObesityPhase 1active not recruiting202564
A Study in Healthy People to Compare How 3 Different Formulations of Survodutide Are Taken up in the BodyPhase 1completed202530
A Study in Healthy People to Compare How 2 Different Formulations of Survodutide Are Taken up in the BodyPhase 1completed202516
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver FibrosisPhase 3recruiting20241800
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have CirrhosisPhase 3recruiting20241590
A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverPhase 1active not recruiting202429
A Study to Test Whether Survodutide Helps Japanese People Living With Obesity DiseasePhase 3completed2024274
A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose WeightPhase 3completed2024307
A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight (SYNCHRONIZE-MASLD)Phase 3completed2024218
A Study to Test Whether Multiple Doses of BI 456906 Have an Effect on Cardiac Safety in People With Overweight or ObesityPhase 1completed2024110
A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney ProblemsPhase 1completed202442
A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or ObesityPhase 1completed202434
A Study in Chinese People With Overweight or Obesity to Test How Different Doses of Survodutide Are Taken up in the BodyPhase 1completed202430
A Study in People With Overweight or Obesity to Test How BI 1820237, BI 456906, or a Combination of Both Affects Brain ActivityPhase 1completed202423
A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)Phase 3completed20235531
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose WeightPhase 3completed2023755
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose WeightPhase 3completed2023726
A Study in Women With Overweight or Obesity to Test Whether Different Doses of BI 456906 Influence the Amount of a Contraceptive in the BloodPhase 1completed202332
A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906Phase 1completed202388
A Study to (1) Compare How BI 456906 is Taken up in the Body of Healthy People and People With Liver Problems and (2) Find Out How People With Overweight and Obesity, With and Without Liver Problems, Tolerate Different Doses of BI 456906Phase 1completed202282
A Study in Healthy Men to Test How BI 456906 is Processed in the BodyPhase 1completed20226
A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)Phase 2completed2021295
A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose WeightPhase 2completed2021387
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.Phase 2completed2020413
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2Phase 1completed202037
A Study to Test Different Doses of BI 456906 in Patients With ObesityPhase 1completed2018131
Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 456906 in Healthy Male VolunteersPhase 1completed201720

Peer-reviewed studies (15)

PaperAuthorsJournalYearType
Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/ObesityEkinci EI et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Survodutide Once Weekly for the Treatment of Adults with Obesityle Roux CW et al.The New England journal of medicine2026Randomized Controlled Trial
Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trialKaplan LM et al.Nature medicine2026Randomized Controlled Trial
Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP TrialYokote K et al.Diabetes, obesity & metabolism2026Clinical Study
Baseline characteristics in the SYNCHRONIZE™-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetesWharton S et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1)le Roux CW et al.Diabetes, obesity & metabolism2026Randomized Controlled Trial
Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m(2) in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonistle Roux CW et al.Diabetes, obesity & metabolism2025Randomized Controlled Trial
Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE™-1 and -2)Wharton S et al.Obesity (Silver Spring, Md.)2025Clinical Study
Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes TrialKosiborod MN et al.JACC. Heart failure2024Clinical Study
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisLawitz EJ et al.Journal of hepatology2024Clinical Trial, Phase I
A Phase 2 Randomized Trial of Survodutide in MASH and FibrosisSanyal AJ et al.The New England journal of medicine2024Randomized Controlled Trial
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trialle Roux CW et al.The lancet. Diabetes & endocrinology2024Randomized Controlled Trial
Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trialBlüher M et al.Diabetologia2024Randomized Controlled Trial
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesityYazawa R et al.Diabetes, obesity & metabolism2023Randomized Controlled Trial
Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906Jungnik A et al.Diabetes, obesity & metabolism2023Clinical Trial, Phase I

More cited research

Conditions researched

Related compounds

FAQ

What is Survodutide?

An investigational long-acting GLP-1 and glucagon receptor dual agonist studied for obesity and metabolic liver disease.

How many registered human trials study Survodutide?

The PeptideWhiz trial index lists 35 registered trials for Survodutide, the most recent from 2026.

How much published research exists on Survodutide?

The PeptideWhiz paper index links 15 PubMed papers to Survodutide; by study type, 32 human and 7 animal studies.

Which conditions is Survodutide researched for?

Fat loss, obesity & body recomposition, Fatty liver & elevated liver enzymes, Insulin resistance, prediabetes & type 2 diabetes, Kidney protection (CKD, diabetic kidney, lupus kidney).

Research and education only. Not medical advice. No dosing guidance. Data: ClinicalTrials.gov registry and PubMed via the PeptideWhiz index (204,289 studies).

Reported dosing ranges from research